MX2022004770A - Vectores de virus adeno-asociados (aav) para el tratamiento de la degeneracion macular relacionada con la edad y otras enfermedades y trastornos oculares. - Google Patents

Vectores de virus adeno-asociados (aav) para el tratamiento de la degeneracion macular relacionada con la edad y otras enfermedades y trastornos oculares.

Info

Publication number
MX2022004770A
MX2022004770A MX2022004770A MX2022004770A MX2022004770A MX 2022004770 A MX2022004770 A MX 2022004770A MX 2022004770 A MX2022004770 A MX 2022004770A MX 2022004770 A MX2022004770 A MX 2022004770A MX 2022004770 A MX2022004770 A MX 2022004770A
Authority
MX
Mexico
Prior art keywords
vectors
age
treatment
related macular
aav
Prior art date
Application number
MX2022004770A
Other languages
English (en)
Inventor
Mark Shearman
Adrian Timmers
Judith Newmark
Steven Pennock
Rakshaa Mureli
Chunjuan Song
Lisa Keyes
Original Assignee
Applied Genetic Tech Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genetic Tech Corporation filed Critical Applied Genetic Tech Corporation
Publication of MX2022004770A publication Critical patent/MX2022004770A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona promotores aislados, casetes de expresión transgénica, vectores, kits y métodos para el tratamiento de la generación macular relacionada con la edad y otras enfermedades genéticas que afectan a las células cónicas de la retina.
MX2022004770A 2019-10-22 2020-10-22 Vectores de virus adeno-asociados (aav) para el tratamiento de la degeneracion macular relacionada con la edad y otras enfermedades y trastornos oculares. MX2022004770A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924338P 2019-10-22 2019-10-22
PCT/US2020/056862 WO2021081203A1 (en) 2019-10-22 2020-10-22 Adeno-associated virus (aav)vectors for the treatment of age-related macular degeneration and other ocular diseases and disorders

Publications (1)

Publication Number Publication Date
MX2022004770A true MX2022004770A (es) 2022-10-07

Family

ID=75586875

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004770A MX2022004770A (es) 2019-10-22 2020-10-22 Vectores de virus adeno-asociados (aav) para el tratamiento de la degeneracion macular relacionada con la edad y otras enfermedades y trastornos oculares.

Country Status (10)

Country Link
US (1) US20210123076A1 (es)
EP (1) EP4048321A4 (es)
JP (1) JP2022553309A (es)
KR (1) KR20230019062A (es)
CN (1) CN115175706A (es)
AU (1) AU2020371663A1 (es)
CA (1) CA3158517A1 (es)
IL (1) IL292379A (es)
MX (1) MX2022004770A (es)
WO (1) WO2021081203A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088579B2 (en) * 2005-02-14 2012-01-03 University Of Iowa Research Foundation Complement factor H for diagnosis of age-related macular degeneration
CN101160412A (zh) * 2005-02-14 2008-04-09 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
WO2007127428A2 (en) * 2006-04-28 2007-11-08 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
CA2659392A1 (en) * 2006-07-13 2008-01-17 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
CN115976105A (zh) * 2015-09-24 2023-04-18 宾夕法尼亚州大学信托人 用于治疗补体介导的疾病的组合物和方法
US20190071477A1 (en) * 2015-12-31 2019-03-07 Quassia Biopharma Co., Ltd Recombinant complement Factor H-immunoglobulin fusion protein with complement regulatory activity, and preparation method therefor and use thereof
GB201706808D0 (en) * 2017-04-28 2017-06-14 Univ Newcastle Modified complement proteins and uses thereof
WO2019079718A1 (en) * 2017-10-20 2019-04-25 Gemini Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION

Also Published As

Publication number Publication date
KR20230019062A (ko) 2023-02-07
EP4048321A1 (en) 2022-08-31
AU2020371663A1 (en) 2022-05-19
EP4048321A4 (en) 2023-11-22
JP2022553309A (ja) 2022-12-22
WO2021081203A1 (en) 2021-04-29
US20210123076A1 (en) 2021-04-29
CA3158517A1 (en) 2021-04-29
IL292379A (en) 2022-06-01
CN115175706A (zh) 2022-10-11

Similar Documents

Publication Publication Date Title
DOP2016000280A (es) Vectores de aav para la terapia génica de la retina y el snc
WO2012094560A3 (en) Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
CR20210444A (es) Composiciones y métodos para tratar distrofia cristalina de bietti
EP4272728A3 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
PH12018502387A1 (en) Adeno-associated virus variant capsids and methods of use thereof
MX2021013486A (es) Viriones de virus adenoasociados con capside variante y metodos para su uso.
PH12021551155A1 (en) Recombinant viral vectors and nucleic acids for producing the same
JP2016535034A5 (es)
MX2018005286A (es) Constructo genetico.
MX2022004771A (es) Vectores de virus adeno-asociados (aav) de triple funcion para el tratamiento de enfermedades asociadas a c9orf72.
EP3870170A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES
MX2021011701A (es) Vectores adenoasociados fabricados por ingenieria (aav) para expresion transgenica.
PH12021550794A1 (en) Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
MX2020010191A (es) Composiciones de virus adenoasociado (aav), métodos de fabricación y métodos de uso.
MX2022004770A (es) Vectores de virus adeno-asociados (aav) para el tratamiento de la degeneracion macular relacionada con la edad y otras enfermedades y trastornos oculares.
WO2019046341A3 (en) Methods and compositions for treating cone-rod retinal dystrophy
NZ745489A (en) Gene therapy for the treatment of a retinal degeneration disease
AU2017259966A1 (en) TrkB agonist antibodies for treating neurodegenerative disorders
MX2021005435A (es) Transgen abcb11 con codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 2 (pfic2).
Nelson et al. CAPN5 gene silencing by short hairpin RNA interference
MX2021010650A (es) Composiciones de materia con actividad para eliminar lipofuscina de células retinales.
EP3752524A4 (en) GENE THERAPY MEDIATED BY AN ADENO-ASSOCIATED VIRUS VECTOR FOR OPHTHALMIC DISEASES
EP4364803A3 (en) Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies